FMC Corporation reported fourth quarter (Q4) 2025 revenue of USD 1.08 billion, reflecting a 12 percent decline compared to the prior year. For the full year (FY) 2025, revenue was USD 3.47 billion, down 18 percent versus the previous year. The company recorded a Q4 2025 GAAP loss of USD 13.74 per diluted share, primarily due to a goodwill impairment. Adjusted earnings per diluted share for Q4 2025 were USD 1.20, a decrease of 33 percent. Adjusted EBITDA for the quarter stood at USD 280 million, 17 percent lower year over year, with an EBITDA margin of 26 percent. Key factors impacting performance included a 6 percent price decline in Q4, mainly in the Rynaxypyr product line, as well as lower volumes driven by increased competition, particularly in Latin America. FMC continued to implement its post-patent strategy for Rynaxypyr and focused on new active ingredient growth. Looking ahead, FMC provided 2026 adjusted earnings per share guidance in the range of USD 1.63 to USD 1.89. The Board of Directors has authorized the exploration of strategic options, including a potential sale of the company, to unlock shareholder value and position the portfolio for long-term success. The company also reaffirmed its commitment to strengthening the balance sheet and enhancing the competitiveness of its core business.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. FMC Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0000037785-26-000036), on February 04, 2026, and is solely responsible for the information contained therein.